Interestingly, lenalidomide downregulated PD-L1 expression on CD38+CD138+ primary MM tumor cells, independent of a direct apoptotic effect, suggesting that dual immunotherapy with CT-011 and lenalidomide may be justified in patients with MM. Here, CD38 is linked to Miyoshi myopathy.